Managing bone parameters in dialysis patients: international guideline conflicts
Related Experiment Video
Updated: Jul 14, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1Renal Unit, Royal Adelaide Hospital and the Department of Medicine, University of Adelaide, South Australia, Australia. rfaull@mail.rah.sa.gov.au
Insights
Bone metabolism (calcium, phosphate, parathyroid hormone) is linked to cardiovascular death in dialysis patients. New guidelines offer differing recommendations on vitamin D and phosphate binders, requiring local context for application.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Bone Metabolism
Background:
- Bone and mineral disorders are prevalent in dialysis patients.
- These disorders are strongly linked to increased cardiovascular mortality.
- Recent guidelines address management of these parameters.
Purpose of the Study:
- To highlight key differences between major international guidelines on bone mineral management in dialysis patients.
- To emphasize the importance of considering local clinical practice and resource availability when applying guidelines.
Main Methods:
- Comparative analysis of recommendations from the Kidney Disease Outcomes Quality Initiative (KDOQI) and Caring for Australasians with Renal Impairment (CARI) guidelines.
- Focus on divergent areas: vitamin D therapy and phosphate binder use.
Main Results:
- Significant differences exist in recommendations regarding vitamin D analogs and phosphate binders between KDOQI and CARI guidelines.
- These discrepancies reflect variations in local practices, reimbursement, and literature interpretation.
Conclusions:
- Clinicians must critically evaluate guideline recommendations in light of their specific clinical environment.
- Tailoring therapy based on local realities is crucial for effective management of bone parameters and cardiovascular risk in dialysis patients.
Abstract:
The linkage between bone parameters (calcium, phosphate, parathyroid hormone) and cardiovascular death in dialysis patients has led to a major resurgence in interest in this area of nephrological practice. Two major groups have recently published extensive guidelines for clinical practice in this area--the National Kidney Foundation's Kidney Disease Outcomes and Quality Initiative from the United States, and the Caring for Australasians with Renal Impairment group from Australia and New Zealand. There are some important differences in their recommendations, which reflect variations in local clinical practice, reimbursement systems, and interpretation of the medical literature. Two areas of divergence are highlighted in this editorial--use of vitamin D and its analogs, and use of phosphate binders. Readers of guidelines such as these need to be careful to interpret such recommendations in the context of the realities of their local clinical practice and availability of therapies.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis III: Nursing Management
Peritoneal Dialysis III: Nursing Management
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
